One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China

Inclusion Criteria: 1. Age 18-85 years (including 18 and 85); 2. Acute ischemic stroke within 24 hours of onset, and NIHSS \>5 points; 3. Acute large vessel occlusion, including internal carotid artery, M1 segment of middle cerebral artery, M2 segment of middle cerebral artery; 4. Multimodal CT/MRI imaging was completed before thrombectomy, and the following criteria were met: penumbra\>10ml, infarct core volume \<70ml, and mismatch rate \>1.2; 5. Planned to receive endovascular treatment; 6. Informed consent was obtained. Exclusion Criteria: 1. History of atrial fibrillation or atrial flutter, or 12-lead ECG before randomization and after admission showing atrial flutter or atrial fibrillation; 2. Treated with intravenous thrombolysis for this stroke or currently taking new oral anticoagulant drugs, warfarin, ticagrelor and other drugs that may increase the risk of bleeding; 3. Pre-stroke disability (pre-stroke mRS score \> 2); 4. Severe comorbidity (such as severe cardiopulmonary dysfunction, or the terminal stage of malignant tumors with expected survival less than 90 days); 5. CT shows hypodensity lesions in more than 1/3 of the territory of the middle cerebral artery; 6. Allergy to tirofiban or having any contraindications to the use of tirofiban (patients with active internal bleeding, history of intracranial hemorrhage, intracranial tumors, arteriovenous malformations, and intracranial aneurysms, or patients resulting in thrombocytopenia from the use of tirofiban previously); 7. Contraindications to the contrast agents used in multimodal CT/MRI examination (such as allergy to the contrast agents, etc.); 8. Pregnant or breastfeeding women; 9. Patients currently participating in other clinical study trials; 10. Other conditions determined by the investigator are not suitable for inclusion in this study.